In recent trading, shares of HCA Healthcare Inc (Symbol: HCA) have crossed above the average analyst 12-month target price of $480.61, changing hands for $491.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on

In recent trading, shares of Amkor Technology Inc. (Symbol: AMKR) have crossed above the average analyst 12-month target price of $30.50, changing hands for $32.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade o

In recent trading, shares of J.B. Hunt Transport Services, Inc. (Symbol: JBHT) have crossed above the average analyst 12-month target price of $162.96, changing hands for $166.43/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to rea

In recent trading, shares of Ross Stores Inc (Symbol: ROST) have crossed above the average analyst 12-month target price of $170.00, changing hands for $174.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on va

In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $100.86, changing hands for $105.33/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on

In recent trading, shares of Regeneron Pharmaceuticals, Inc. (Symbol: REGN) have crossed above the average analyst 12-month target price of $755.22, changing hands for $755.90/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react:

(RTTNews) - Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company, announced Mondday that it has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.

In recent trading, shares of Sionna Therapeutics Inc (Symbol: SION) have crossed above the average analyst 12-month target price of $42.00, changing hands for $43.66/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade

Inflation can significantly erode the buying power of cash and threaten households' savings over the long term.

BHP made one last-gasp attempt to seduce Anglo but it looks like they have now accepted defeat.

Potential Fed rate cut in December could reignite a ‘risk-on’ flame. Why the market looks to be in ‘early 1999’.

Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s.

Carvana’s stunning rebound is facing its biggest test yet: Amazon.

Key PointsSocial Security benefits will increase by 2.8% beginning in 2026.

Key PointsAMD's data center division has lagged behind Nvidia's since the AI arms race began.

Key PointsShifting consumer tastes have plagued this staples stock.

Key PointsAlphabet is poised to continue its strong profit growth in the years ahead.

(RTTNews) - Despite coming off early highs, Germany's benchmark DAX is up firmly in positive territory on Monday, amid renewed hopes of a Fed interest rate in December, and signs of progress in Ukraine peace talks.

Key PointsThe contribution limits for 401(k)s are rising in 2026.

Key PointsRelative to the S&P 500, MGM Resorts International has underperformed over the past 1, 3, and 5 years.

(RTTNews) - The French stock market is down marginally a little past noon on Monday, after having opened on a firm note amid renewed hopes of an interest rate cut by the Federal Reserve in December, and optimism surrounding Ukraine peace talks.

Many retirees soon must take required minimum distributions and mistakes can be costly. Here's how to avoid them.

A 1963-era calculation no longer makes sense, one strategist says.

Fading investor belief may be one of the biggest obstacles for bitcoin to overcome, says Deutsche Bank.

Shares of Novo Nordisk on Monday fell 10% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.